References
Gladman D, Urowitz M. Clinical features of systemic lupus erythematosus. In: Hochberg M, Silman A, Smolen J, et al, editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 417–37
Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging 2007; 24(9): 701–15
Kammer GM, Mishra N. Systemic lupus erythematosus in the elderly. Rheum Dis Clin North Am 2000; 26(3): 475–92
Freedman GM. Chronic pain: clinical management of common causes of geriatric pain. Geriatrics 2002; 57(5): 36–41
Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11(6): 340–7
Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9
The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324(3): 150–4
Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10(3): 140–7
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44(7): 1496–503
Aranow C, Ginzler EM. Treatment of constitutional symptoms, skin, joint, serositis, cardio-pulmonary, hematologic and central nervous system manifestations In: Hochberg M, Stilman A, Smolen J, et al., editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 439–48
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353(21): 2219–28
Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314(10): 614–9
Krensky AM, Vincenti F, Bennett WM. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL, editor in chief. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc., 2006: 1405–31
Van Vollenhoven RF, Morabito LM, Engleman AG, et al. Treatment of systemic lupus erythematous with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25(2): 285–9
Rauova L, Likac J, Rovensky J, et al. High-dose intravenous immunoglobulins for lupus nephritis: salvage immunomodulation. Lupus 2001; 10: 209–13
Rights and permissions
About this article
Cite this article
Early detection and individualized treatment of elderly-onset systemic lupus erythematosus optimizes symptom control. Drugs Ther. Perspect 24, 13–16 (2008). https://doi.org/10.2165/00042310-200824060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200824060-00004